Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
4.540
-0.160 (-3.40%)
Mar 31, 2025, 10:39 AM EDT - Market open
Precision BioSciences Revenue
In the year 2024, Precision BioSciences had annual revenue of $68.70M with 40.98% growth. Precision BioSciences had revenue of $638.00K in the quarter ending December 31, 2024.
Revenue (ttm)
$68.70M
Revenue Growth
+40.98%
P/S Ratio
0.47
Revenue / Employee
$630,239
Employees
109
Market Cap
47.59M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
DTIL News
- 5 days ago - Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update - Business Wire
- 10 days ago - Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025 - Business Wire
- 11 days ago - Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025 - Business Wire
- 12 days ago - Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - Business Wire
- 14 days ago - Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B - Business Wire
- 19 days ago - iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting - Business Wire
- 5 weeks ago - Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - Business Wire
- 5 weeks ago - Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate - Benzinga